Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Richter transformation, T-cell leukemia, T-cell prolymphocytic leukemia, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic/myeloproliferative disease, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, primary myelofibrosis, prolymphocytic leukemia, vascular disorder, vascular hemostatic diseaseRecruitingPhase 12026-05-05NCT04771572

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Newave Pharmaceutical Inc5

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Cincinnati Children's Hospital Medical CenterCincinnatiUnited States405
Dana Farber Cancer InstituteBostonUnited States300
MD Anderson Cancer CenterHoustonUnited States589
The Ohio State UniversityColumbusUnited States191
University of ChicagoChicagoUnited States312
University of CincinnatiCincinnatiUnited States5
University of North CarolinaChapel HillUnited States38
University of UtahSalt Lake CityUnited States137